It is now the first and only Tdap vaccine in the US approved for a repeat dose in people 10 through 64 years of age eight years or more after the first vaccination. Adacel is also the only Tdap vaccine available in a syringe made without natural rubber latex, which may help reduce risk to patients with an allergy.
The FDA licensure was based on clinical data from a study of the safety and effectiveness of repeat Adacel vaccination in adults.
In the study of more than 1,300 adults (aged 18 through 64 years), participants received either Adacel vaccine or a tetanus-diphtheria vaccine 8-12 years after a previous dose of Adacel vaccine.
The results of the study published in the Journal of the Pediatric Infectious Diseases Society showed a second dose of Adacel vaccine in adults administered 8-12 years after a previous dose found no significant differences in adverse events between vaccine groups.
A total of 87.7% of Tdap vaccine recipients (n=999) and 88.0% of Td vaccine recipients (n=328) reported at least 1 injection-site reaction.
Sanofi Pasteur has provided the results of the study to the CDC's Advisory Committee on Immunization Practices for their consideration in future recommendations.
The US Centers for Disease Control and Prevention currently recommends a single dose of Tdap vaccine for adolescents and adults, and for pregnant women during every pregnancy.
Tdap helps protect adolescents and adults and may prevent the spread of the infection to babies and young children who are still building immunity.5 Despite the CDC-recommendation, nearly three of four adults have not received the Tdap vaccine.
Adacel vaccine is given to people 10 through 64 years of age to help prevent tetanus (lockjaw), diphtheria, and pertussis (whooping cough).
Quanterix partners with leading health networks for Alzheimer's diagnosis advancements
Precision BioSciences reports FDA pre-IND feedback for PBGENE-HBV
VBI to sell manufacturing capabilities and enter new license agreement with Brii Biosciences
Ondine Biomedical's Steriwave shows promise in nasal pathogen reduction
BioSenic expands patent coverage for ATO therapeutic platform
PacBio unveils Nanobind PanDNA kit for enhanced DNA extraction solutions
Sequentify receives funding from Israel Innovation Authority
INOVIO plans BLA submission for INO-3107 as RRP treatment
ImmunityBio secures USD320m investment from Oberland Capital
Poolbeg Pharma prioritises promising RSV drug candidates identified through AI-led analysis
GHIT fund invests JPY500m in antimalarial drug clinical trial
AstraZeneca agrees acquisition of Icosavax
Versameb names new chairman of the board
Kling Bio appoints Dr Stefano Gullà as chief scientific officer